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After cardiac stress such as that occurring during myocardial infarction the heart 
undergoes pathological remodelling consisting of cardiomyocyte hypertrophy, interstitial 
fibrosis, contractile dysfunction, cell death and ventricular dilatation. It is due to this 
remodelling that the survivability is 10% at 10 years post-infarction. In this study we 
explored the possible cardioprotective effects of melanocortin receptor activation in an 
initial search for a treatment for cardiac remodelling. ELISA tests were used to study the 
signalling cascade of melanocortin receptor activation and qPCRs were used to study 
gene expression changes. Using an established rat cardiomyocyte cell line and primary 
mouse cardiomyocytes it was established that activation of all melanocortin receptors 
results in a cardioprotective response through the downregulation of pro-hypertrophic 
genes. We were also able to determine through independent activation of the receptors 
for melanocortins that the receptors for melanocortin 1 and 5 were the ones responsible 
for the cardioprotective response, with melanocortin receptor 5 activation providing the 
strongest cardioprotective effect. Further study of these receptors and their 
cardioprotective effects could lead to a treatment for cardiac hypertrophy. 
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1.1Forms of hypertrophy and heart failure 
Globally, heart failure has already become an epidemic. It is an increasingly common 
condition in the developed world and its associated comorbidities are a rising cause of 
death. After diagnosis of heart failure, the 5 year survival rate is 50% and drops to only 
10% at 10 years post-diagnosis (Roger, 2013). It is therefore of crucial importance to 
study the underlying causes and mechanisms that lead to cardiac failure to improve the 
symptoms and prognosis of affected patients. 
Cardiac hypertrophy is associated with heart failure and with negatively progressing 
outcomes of the disease. Left ventricular hypertrophy was observed in up to 20% of the 
general population in the nineties and has since been shown to rise up to 30% (Cramariuc 
and Gerdts, 2016). This is a worrying trend as there is no good treatment after the onset 
of cardiac hypertrophy and it is a herald of worsening symptoms and disease. 
The main reason for the lack of treatment of hypertrophy is that cardiomyocytes finish 
differentiating in neonates and thereafter any increase in the size of the cardiac walls is 
through an increase in size of those cardiomyocytes. Once the heart starts deteriorating 
there is not much the body can do to revert it (Engel, 2005). Hypertrophy is a response to 
increased heart wall stress, in an attempt to increase the capacity of the heart and maintain 
the increased workload hypertrophy takes place. This hypertrophy can be benign, such as 
that seen in athletes who perform extended exercise sessions, or pathological. Non-
pathological hypertrophy, also known as physiological, is characterized by an increased 
contractile function without fibrosis or cell death and is reversible and does not lead to 
heart failure. A summary of non-pathological cardiac hypertrophy subtypes can be found 
on Figure 1. It is common amongst high-performance athletes, with eccentric hypertrophy 
appearing in endurance training and concentric hypertrophy appearing in strength training 





Figure 1. Graphical summary of hypertrophy subtypes. The abbreviations stand for Eccentric Hypertrophy (EH), Left 
Ventricle (LV), Concentric Hypertrophy (CH). Cardiac hypertrophy can take place as an adaptation to volume 
overload, in which case the LV experiences elongation of the cardiomyocytes and increase of the ventricular volume 
while retaining the same wall thickness. If the primary stimulus is a pressure overload however, the heart will respond 
through the proliferation of cardiomyocytes and the thickening of the cell walls. 
 
Pathological hypertrophy on the other hand is commonly a result of disease and is 
maladaptive. Pathological hypertrophy appears after abnormal haemodynamic stress (e.g. 
systemic hypertension and aortic stenosis (Samak et al., 2016)) and leads to imbalanced 
hypertrophy and can progress to heart failure. It is therefore important to know what 
mechanisms trigger this maladaptation to find potential ways of reverting it once it occurs 
(Samak et al., 2016; Shimizu and Minamino, 2016).  
Heart failure has many clinical phenotypes, and a useful distinction is between heart 
failure with preserved ejection fraction (HFpEF) and with reduced ejection fraction 
(HFrEF). HFpEF is mostly observed in women (Abebe et al., 2016) and is associated with 
valvular and hypertensive heart pathologies, obesity and diabetes. It has been reported 
that oestrogen has a protective effect on endothelial dysfunction and furthermore has anti-
proliferative effects on vascular smooth muscle, which explains why HFpEF is more 
common in older women (Simmonds et al., 2020). HFrEF is described when the ejection 
fraction decreases below 40 %. HFrEF is mostly present in male patients (Abebe et al., 
2016) and presents with ischemic heart disease and dilated cardiomyopathy. HFrEF is 
associated with cardiac hypertrophy and worsened clinical outcomes. HFrEF incurs in 
cardiomyocyte loss through apoptosis and necrosis. After ischaemia there is an initial cell 
death which causes inflammation and further cell death. This pronounced cell death and 
inflammatory situation promotes further cardiac remodelling and enhances fibrosis.  
Pathological hypertrophy is initially compensatory but quickly progresses to include 
ventricle dilation and cardiomyocyte lengthening and contractile dysfunction. 
Hypertrophy is also exacerbated by increased fibrosis, cardiomyocyte death and changes 
in Ca2+ metabolism. HFrEF is further characterized by a fibrotic increase as a result of 
cardiomyocyte death. HFpEF fibrosis however is caused by increased deposition of 
 
collagen type I (which confer increased tensile strength) to the detriment of collagen type 
III (which is more flexible). 
1.2 Markers and mediators of hypertrophy 
Pathological hypertrophy is characterized by a switch to a foetal gene expression profile, 
this consists of increased expression of atrial natriuretic peptide (ANP), brain natriuretic 
peptide (BNP), myosin heavy chain and skeletal muscle α-actin (αSKA). This switch to 
foetal gene expression also includes a shift into carbohydrate-based energy production 
instead of the traditional lipid-based metabolism (Samak et al., 2016). Hypertrophy is also 
linked with inflammation and expression of pro-inflammatory cytokines (IL-6 
(Interleukin 6), Interleukin-1β, Interleukin 1 receptor antagonist and TNFα) (Kuusisto et 
al., 2012). Conversely, physiological hypertrophy does not involve an increase in these 
markers and may even present with a decrease in their expression. 
BNP is a hormonal peptide secreted by cardiomyocytes when they are stretched due to 
increased ventricular volume. Once released, it binds to the atrial natriuretic factor 
receptor in a fashion similar to ANP. Its biological activity differs from ANP; BNP has a 
lower affinity, but longer biological half-life and it causes a decrease in vascular 
resistance and central venous pressure. In the heart, the effect of natriuretic factor receptor 
activation leads to a protective effect against hypertrophy as blocking of this receptor 
leads to cardiac fibrosis (Oliver et al., 1997). It has been shown that congestive heart 
failure is linked with a sustained increase in plasma BNP, myocardial hypertrophy and 
left ventricle stiffness (Tamura et al., 2000). 
One of the most well-studied hypertrophic agents is angiotensin II. The pro-hypertrophic 
effect of angiotensin II is mediated through an increase in the expression of TGF-β 
(Schultz et al., 2002). It is known that Tgfb1 mRNA levels are increased upon pressure 
overload or drug-induced hypertrophy. 
Alpha smooth muscle actin (αSMA) is a marker for cardiac remodelling and its 
expression is highest during embryonic development and is reactivated later in life when 
there is production of new cardiomyocytes  (Nagamoto et al., 2000; Ma et al., 2012). Both 
αSMA and αSKA are the predominant actin isoforms in cardiac sarcomeres. Increase in 
αSKA expression has been linked to cardiac hypertrophy and it constitutes a well-
accepted marker for cardiac hypertrophy in both humans and rodents (Driesen et al., 2009; 
Black et al., 1991).  
 
TGF-β is associated with fibrosis and hypertrophy in mouse hearts when it is 
overexpressed (Dobaczewski et al., 2011). TGF-β, however, is known to be one of the 
most pleiotropic peptides and it can exert many different effects in different tissues or in 
the same tissue when under different conditions or concentrations (Letterio and Roberts, 
1998). TGF-β upregulation through angiotensin II signalling is known to take place but 
it is yet unknown whether this upregulation results in the expression of functional TGF-
β or if another signal is still needed to produce the functional peptide (Campbell and 
Katwa, 1997). Decrease in TGF-β expression cannot be definitively linked to a protective 
effect on the heart. Among other mechanisms, it is known that TGF-β inhibits nitric oxide 
synthase 2 (NOS2) expression (Umar and Van Der Laarse, 2010; Lowenstein and 
Padalko, 2004). 
Nitric oxide (NO) is a mediator in cardiac signalling and is known to have a protective 
effect on cardiomyocytes. In vivo, it is known that pressure overload induces NOS2 
activity in cardiomyocytes which produces an increase in NO levels. In heart failure, the 
levels of NO exceed those with protective effects and become toxic, leading to a 
production of reactive oxygen and nitrogen species (Umar and Van Der Laarse, 2010; 
Nathan, 1997). The increase in NOS2 expression mediated by cytokines in cardiac failure 
leads to apoptosis of cardiomyocytes. 
It is known that angiotensin II promotes the activation of fibroblasts to promote their 
switch to myofibroblasts and their production of extracellular matrix. The effect of 
angiotensin II is mediated through production of TGF-β. Endothelin I is also involved in 
extracellular matrix production and myoblast differentiation, downstream of the TGF-β 
effect. Furthermore, angiotensin II induces endothelin I expression through activation of 
extracellular signal-regulated kinase (ERK) and reactive oxygen species. Because 
angiotensin II is higher on the signalling cascade, it is considered to have greater 
hypertrophic effect than endothelin I (Leask, 2010). 
Agonists of β1-adrenoceptor such as isoprenaline also cause cardiac hypertrophy. 
Isoprenaline is routinely used to induce hypertrophy and fibrosis both in vivo and in vitro 
(Weil et al., 2006; Yin et al., 2009). Phenylephrine also causes re-expression of 
embryonic cardiac genes β-myosin heavy chain and ANP). Both, isoprenaline and 
phenylephrine, cause cardiac hypertrophy through a signalling cascade involving ERK in 
the same manner as angiotensin II and endothelin I. Due to the shared signalling and 
identical outcomes, all four are used interchangeably as hypertrophic agents (Yue et al., 
2000).  
 
Type 3 collagen (Collage, type 3, alpha 1 or Col3A1) is a homotrimeric protein that 
constitutes a major structural component of blood vessels. Its expression is increased in 
cardiac hypertrophy caused by pressure overload as it presents with increased deposition 
of extracellular matrix. 
C-C motif chemokine Ligand 2, also known as monocyte chemoattractant protein 1, is a 
chemokine that recruits monocytes, memory T cells and dendritic cells to the sites of 
inflammation.  
IL-6 is produced in response to tissue damage to produce a pro-inflammatory response 
which limits host damage. This pro-inflammatory response, if maintained, leads to 
chronic inflammation and fibrosis. This general aspect of IL-6 effect is also replicated in 
the heart where reduced IL-6 expression is linked with protective effects after acute 
damage such as myocardial infarction while a sustained IL-6 response results in 
maladaptive fibrosis (Fontes et al., 2015).  
1.3 Melanocortin receptors in the body 
Melanocortins are a family of peptide hormones that originate from the cleavage of a 
single precursor protein known as proopiomelanocortin (POMC). Melanocortins include 
adrenocorticotropic hormone (ACTH) and melanocyte-stimulating hormones (α, β and γ-
MSH), an overview of the cleavage products of POMC can be found in Figure 2. 
Melanocortins mediate their biological actions via five different melanocortin receptors 
(Mc1R-Mc5R) that are found throughout the body.  
 
Figure 2. Overview of the cleavage products of POMC. Outlined in bold are the main melanocortin stimulating 
peptides. POMC is first cleaved into γMSH, ACTH and β-LPH (Beta Lipotropin). ACTH is then further cleaved into 
αMSH and CLIP (Corticotropin-Like Intermediate Peptide). Β-LPH is cleaved into γ-LPH (Gamma Lipotropin) and β-
End (Beta Endorphin. γ-LPH is processed into β-MSH. 
 
Melanocortin receptors are G-protein-coupled receptors that take part in very diverse 
processes including pigmentation, inflammation, energy homeostasis and stress response 
(Cooray and Clark, 2011). Melanocortin effects in the body are still being unveiled, with 
new effects in different tissues being discovered continuously. The wide range of 
activities and pathways in which melanocortins are involved is explained by the existence 
of accessory proteins and the ability of the melanocortin receptors to recognise multiple 
agonistic and antagonistic ligands.  
A brief overview of the known roles of melanocortins will be useful to understand the 
role of these proteins in the organism: Mc1R is responsible for the expression of 
eumelanin and the darkening of skin and hair (Cone, 2006),  Mc2R activation leads to the 
expression of steroidogenesis in the adrenal gland (Thistlethwaite et al., 1975), Mc3R and 
Mc4R are mainly located in the nervous system and have effects on obesity and pain 
(Mountjoy, 2010; Feng et al., 2005; Starowicz et al.) and Mc5R was linked to thermal 
regulation and hair lipid production (Trotta et al., 2018; Abdel-Malek, 2001). 
Melanocortin receptors are known to be expressed also in the heart but their functional 
role is still unclear (Chhajlani, 1996; Getting et al., 2004; Trotta et al., 2018). 
Mc1R has been thoroughly studied for its effect on human pigmentation. Studies have for 
the most part centred on allelic variations of this locus as it accounts for striking mutations 
such as red hair pigmentation and the linked increase in melanoma risk. Mc1R however 
also has an effect on many paracrine systems, like most G-protein-linked receptors it can 
engage in many different signalling pathways. Whether through promiscuous coupling 
with different G-proteins, ligand-induced interactions with β-arrestins or other 
scaffolding proteins (Herraiz et al., 2017). Most of the known effects of Mc1R signalling 
start with G-protein-dependant adenyl cyclase activation. 
Mc3R has been found to play a role in energy metabolism as loss of function mutations 
cause increased fat content and decreased muscle mass without significant changes in 
overall weight (Humphreys et al., 2011). Furthermore, Mc3R has also been shown to 
increase expression after increased sodium intake. 
Mc4R is known to protect from obesity as deficiency in this gene produces increased 
body fat, hyperphagia and hyperinsulinemia (Gonçalves et al., 2018). It has been proven 
that different Mc4R agonists produce different downstream signalling cascades, showing 
that each agonist produces a unique response although they all bind to the same receptor. 
This property hasn’t been yet confirmed for other MCRs (Girardet and Butler, 2014). 
 
1.3.1 Melanocortins used in this research 
Alpha melanocyte-stimulating hormone (α-MSH) was used as a general activator for all 
melanocortin receptor subtypes. Although generally considered a pan-agonist, α-MSH 
has a different affinity for all melanocortin receptors, ranging from very strong to almost 
negligible. In decreasing α-MSH affinity order the melanocortin receptors are Mc1R, 
Mc3R, Mc5R, Mc4R and Mc2R (Cooray and Clark, 2011). 
All MCR subtypes were individually activated in this study except for Mc2R. The 
agonists used to activate the melanocortin receptors were LD211 (a synthetic Mc1R 
agonist), γ-MSH (a natural Mc3R agonist), THIQ (a synthetic Mc4R agonist) and PG 901 
(a synthetic MC5 agonist). A summary for all the melanocortin receptor binding relevant 
to this study can be found in Figure 3 
 
Figure 3. Summary of melanocortin receptors and their agonists. αMSH is a pan-agonist that activates all melanocortin 




2.1 Melanocortin signalling studies 
The project was started by studying the possible signalling pathways activated by 
different melanocortin receptor agonists. For this purpose, the rat cardiomyocyte cell line 
H9c2 was first used and assayed for the phosphorylation status of different mitogen-
activated protein kinases such as ERK and JNK using a commercial ELISA kit.   
The first experiment was performed to test the effects of α-MSH at a fixed 0.1 nM (-10 
M) concentration in H9c2 cells.  The first time the effects of α-MSH at differing times 
were studied, there was no change in any of the kinases studied, these results can be found 
in Figure 4 (a-c). This lack of response went against what was expected as there had been 
some preliminary results previously carried out in the research group that hinted at some 
kind of effect; therefore, the experiments were repeated. To improve the quality of the 
data the 5-minute time point was removed and the space in the ELISA plate previously 
 
taken by that time point was spread within the other times. The reasoning behind the 
removal of this time point is that the whole assay process and sample collection causes a 
delay between wells which exceeds 5 minutes and therefore can’t be fully corrected by 
staggering the treatment initiation times to account for the collection delays. As can be 
seen in Figure 4 (d-f), there was no significant response to α-MSH. There appears to be 
no effect caused by α-MSH at -10M on the levels of pERK. In 4e there appears to be a 
tendency towards a decrease of pJNK with increasing time, the same tendency seems to 
take place in 4f. These downward tendencies however are not significant and were 
completely non-existent in the first -10M α-MSH study at Figure 4 a-c. The lack of 
response in these initial studies prompted a shift in what angle to study the signalling 
cascade from.  
 
 
Figure 4. The effects of αMSH on p-ERK, pJNK and p-CREB in H9c2 cells. Results from phosphorylated ERK (a), JNK 
(b) and CREB (c) at different incubation times (5, 15, 30 and 60 min) after a treatment with a single concentration of 
0.1 nM of α-MSH. Results are shown normalized by the total protein ammount as assayed by a BCA total protein assay 
and as a % of the control, presented are 4 replicates per timepoint. Data is presented as mean ± SEM. Results from 
phosphorylated ERK (d), JNK (b) and CREB (c) at different incubation times (15, 30 and 60 min) after a treatment 
with a single concentration of 0.1 nM of α-MSH. Results are shown normalized by the total protein ammount as assayed 
by a BCA total protein assay and as a % of the control, presented are 5 replicates per timepoint. Data is presented as 
mean ± SEM. 
  
One hypothesis for the varying results between replicates was that the cell line failed to 
correctly replicate the signalling cascade that would have been seen in wild-type cells and 
was instead producing inconsistent phosphorylation of the cascade intermediaries. To test 
   
 
this hypothesis and to confirm whether this lack of response was characteristic of 
cardiomyocytes, a second round of experiments were carried out as replicates of the first 
but using primary neonatal mouse cardiomyocytes. In these tests all parameters, except 
the cell type, were the same.  
There appeared to be a tendency towards a decrease in pJNK and pERK at 5 and 15 
minutes due to α-MSH (Figure 5a, b). Yet the decrease was not significant, at this point 
we resolved to test whether or not there was a confounding effect exerted by contradictory 
effects of different melanocortin receptor subtypes. The first melanocortin subtype 
agonist tested was PG 901. The effects of this melanocortin agonist had much stronger 
and clearer effects than those of α-MSH. In Figure 5d PG 901 was seen to cause a decrease 
in ERK phosphorylation which was most marked at the 60-minute time point. Figure 5e 
shows a marked decrease in pJNK levels at 15 and 60 minutes, the strong effects of this 




















































































































































































































Figure 5. The effects of αMSH on p-ERK, pJNK and p-CREB in mouse neonatal primary cardiomyocytes. Results from 
phosphorylated ERK (a), JNK (b) and CREB (c) at different incubation times (5, 15, 30 and 60 min) after a treatment 
with a single concentration of 0.1 nM of α-MSH. Results are shown normalized by the total protein ammount as assayed 
by a BCA total protein assay and as a % of the control, presented are 5 replicates per timepoint. Data are presented 
as mean ± SEM. Results from phosphorylated ERK (d), JNK (e) and CREB (f) at different incubation times (5,15, 30 
and 60 min) after a treatment with a single concentration of  10 nM of PG 901. Results are shown normalized by the 
total protein ammount as assayed by a BCA total protein assay and as a % of the control, presented are 5 replicates 
per timepoint. Data are presented as mean ± SEM. One asterisk above a column denotes a P value lower than 0.05 
when comparing that column to the control using a one-way ANOVA and a later Tukey multiple comparison test. Two 
asterisks denote a P value lower than 0.01 and three denote a P value lower than 0.001. 
 
 
Mc1R activation through LD211 can be seen in Figure 6. The decreases in pJNK levels 
at 5 and 15 minutes seen in 6b appear in the same line as the decreases seen in 5b and 5e. 
Based on this it was postulated that both Mc1R and Mc5R were chiefly responsible for 
the melanocortin effects upon the myocardial tissue and appeared to be exerting an effect 
in the same direction and through similar signalling pathways. 
 
Figure 6. The effects of LD211 on p-ERK, pJNK and p-CREB in mouse neonatal primary cardiomyocytes. Results from 
phosphorylated ERK (a), JNK (b) and CREB (c) at different incubation times (5, 15, 30 and 60 min) after a treatment 
with a single concentration of 10  nM of LD211. Results are shown normalized by the total protein ammount as assayed 
by a BCA total protein assay and as a % of the control, presented are 5 replicates per timepoint. Data are presented 
as mean ± SEM. One asterisk above a column denotes a P value lower than 0.05 when comparing that column to the 
control using a one-way ANOVA and a later Tukey multiple comparison test. Two asterisks denote a P value lower 
than 0.01 and three denote a P value lower than 0.001. 
 
To continue with the study of the effects of melanocortins, the focus of the research 
moved to quantifying changes in mRNA levels of hypertrophy and inflammation markers 
with qPCR.  
2.2 Gene expression studies 
2.2.1 α-MSH treatments in H9c2 cell line 
Due to the high volume of qPCR results produced, only those with statistically significant 
changes or those having importance in comparisons between cell types was included in 
this section. All other qPCR results are presented in the Annex 1. Applied concentrations 
were the same as in signalling experiment but the treatment times used were increased 
since changes in gene expressions take longer to appear than phosphorylation of kinase 















































































































Figure 7. Compilation of results from qPCR tests performed on H9c2 cells after 3 hours of incubation with α-MSH. 
The genes assayed were αSMA (alpha smooth muscle actin), αSKA (alpha skeletal muscle actin), Nppb (ventricular 
natriuretic peptide) and TGF-β (transforming growth factor beta). One asterisk above a column denotes a P value 
lower than 0.05 when comparing that column to the control using a one-way ANOVA and a later Tukey multiple 
comparison test. Data are presented as mean ± SEM, presented are 5 replicates per study condition and 6 for the 
controls. 
In the first batch of qPCR results, a variable concentration of α-MSH was used to induce 
a response in H9c2 cells after 3h of incubation. Shown in  Figure 7, the pan-agonist has 
no effect on the hypertrophic markers αSMA, αSKA or TGF-β. The treatment however 
caused an increase in Nppb expression at the -10 M concentration. 
After the concentration series, a time series with a fixed 10 nM (-8 M) concentration of 
α-MSH was performed. In Figure 8, a decrease in the expression of both αSMA and αSKA 
can be seen after 1h of incubation with α-MSH. The expression change in Nppb observed 
in 8c went against the change seen in the 7c as there is a decrease at 1 h and a smaller, 
non-significant decrease at 3 h. TGF-β expression is also decreased after both 1 h and 3 
h treatment. From these results, it is clear that α-MSH evokes inconsistent responses as 




























































































































































































































































Figure 8. Compilation of results from qPCR tests performed on H9c2 cells after incubation with -8 M α-MSH at 
different times. The genes assayed were αSMA (alpha smooth muscle actin), αSKA (alpha skeletal muscle actin), Nppb 
(ventricular natriuretic peptide) and TGF-β (transforming growth factor beta). One asterisk above a column denotes 
a P value lower than 0.05 when comparing that column to the control using a one-way ANOVA and a later Tukey 
multiple comparison test. Two asterisks denote a P value lower than 0.01. In a column in graph 5c the P value is shown 
as although not showing statistical significance it showed a clear decrease and was just on the border of being 
considered significant. Data are presented as mean ± SEM, presented are 5 replicates per study condition and 6 for 
the controls. 
 
2.2.2. α-MSH treatments in primary neonatal mouse cardiomyocytes 
The same time and concentration series performed in H9c2 cells were performed in 
primary cardiomyocytes. The tests on primary cells were started by performing α-MSH 
concentration series after 3 h of incubation. In Figure 9, a decrease in interleukin 6 (IL-
6) expression was observed after treatment with 10 nM (-8 M) concentration of α-MSH. 




Figure 9. Compilation of results from qPCR tests performed on primary neonatal mouse cardiomyocytes after 3 hours 
of incubation with α-MSH. The genes assayed were IL-6 (interleukin 6), TNFα (Tumour necrosis alpha), αSMA (Alpha 
smooth muscle actin) and TGF-β (Transforming growth factor beta). One asterisk above a column denotes a P value 
lower than 0.05 when comparing that column to the control using a one-way ANOVA and a later Tukey multiple 
comparison test. Data are presented as mean ± SEM, presented are 5 replicates per study condition and 6 for the 
controls. 
 
In Figure 10, a very strong decrease in αSMA can be seen both after 1 and 3 hours of 
incubation with 10 nM (-8 M) α-MSH. This decrease is in line with effect seen in the 
H9c2 cells. Furthermore, TGF-β expression showed a decrease after both 1 and 3 hours 
of incubation with α-MSH, which parallels the effect seen on H9c2 cells. Nppb expression 



























































































































Figure 10. Compilation of results from qPCR tests performed on primary neonatal mouse cardiomyocytes after 
incubation with -8 M α-MSH at different times. The genes assayed were αSMA (alpha smooth muscle actin), Col3A1 
(collagen 3A1), Nppb (ventricular natriuretic peptide) and TGF-β (transforming growth factor beta). One asterisk 
above a column denotes a P value lower than 0.05 when comparing that column to the control using a one-way ANOVA 
and a later Tukey multiple comparison test. Two asterisks denote a P value lower than 0.01 and three denote a P value 
lower than 0.001. Data are presented as mean ± SEM, presented are 5 replicates per study condition and 6 for the 
controls. 
 
2.2.3 Subtype specific melanocortin receptor agonist treatments in H9c2 cell line 
H9c2 cells were used to evaluate the effects of individual melanocortin receptor 
activation.   In Figure 11, non-significant decreases were observed in αSMA and αSKA 
after treatment with the Mc5R agonist PG 901. Furthermore, PG 901 clearly reduced 





























































































































































































































































































































Figure 11. Compilation of results from qPCR tests performed on H9c2 cells after incubation with -8 M of different 
melanocortin receptor agonists for 3h. The genes assayed were αSMA (alpha smooth muscle actin), αSKA (alpha 
skeletal actin), Nppb (ventricular natriuretic peptide) and TGF-β (transforming growth factor beta). One asterisk above 
a column denotes a P value lower than 0.05 when comparing that column to the control using a one-way ANOVA and 
a later Tukey multiple comparison test. In the PG 901 columns in graph 12a and 12b the P value is shown as the results 
were in line with those expected and were used to reach the study conclusions, the exact P value was added for 
transparency. Data are presented as mean ± SEM, presented are 4 replicates per study condition and 6 for the controls. 
 
 
In Figure 12, an increase in IL-6 expression can be seen after incubation with γ-MSH 
while a decrease can be seen after incubation with PG 901. NOS2 expression was also 
reduced by PG 901, while LD211 and γ-MSH increased its expression. Furthermore, 
Col3A1 expression was decreased after treatment with γ-MSH and PG 901. Overall, 
Mc5R activation with PG 901 induced strongest gene expression changes in H9c2 cells.  
 
 
Figure 12. Compilation of results from qPCR tests performed on H9c2 cells after incubation with -8 M of different 
melanocortin receptor agonists for 3h. The genes assayed were IL-6 (interleukin 6), NOS2 (nitric oxide synthase 2), 
Col3A1 (collagen 3A1) and CCL2 (chemokine C-C motif ligand 2). One asterisk above a column denotes a P value 
lower than 0.05 when comparing that column to the control using a one-way ANOVA and a later Tukey multiple 
comparison test. Two asterisks denote a P value lower than 0.01. Data are presented as mean ± SEM, presented are 4 
replicates per study condition and 6 for the controls. 
2.2.4 Subtype specific melanocortin receptor agonist treatments in primary 
cardiomyocytes 
The melanocortin receptor agonist treatments were also repeated in primary 
cardiomyocytes and the results can be seen in Figure 13. The effect of PG 901 on αSMA 
expression is stronger than that seen in H9c2 cells. Furthermore, the Mc1R agonist LD211 
evoked a similar response as PG 901. The effect on NOS2 expression was negligible and 
did not follow the findings seen in the H9c2 cell line. The decrease in IL-6 expression 
caused by PG 901 is even more marked in the primary cardiomyocytes than in the H9c2 
cell line, while the increase in expression caused by γ-MSH is not replicated. A decrease 
in IL-6 expression is also seen with LD211 treatment, an effect that was not observed in 































































































































































































Figure 13. Compilation of results from qPCR tests performed on primary neonatal cardiomyocytes after incubation 
with -8 M of different melanocortin receptor agonists for 3h. The genes assayed were αSMA (alpha smooth muscle 
actin), NOS2 (nitric oxide synthase 2), IL-6 (interleukin 6) and Nppb (ventricular natriuretic peptide). One asterisk 
above a column denotes a P value lower than 0.05 when comparing that column to the control using a one-way ANOVA 
and a later Tukey multiple comparison test. Two asterisks denote a P value lower than 0.01. Data are presented as 
mean ± SEM, presented are 4 replicates per study condition and 6 for the controls. 
To further study the effects of Mc1R activation seen in the previous experiments in 
primary cardiomyocytes, primary cardiomyocytes were further screened for 
concentration-responsiveness after a 3h treatment with LD211. The results are shown in 
Figure 14. Surprisingly, the decreases seen in αSMA, IL-6 and Nppb in the different 
melanocortin agonist experiment were not fully replicated in this experiment. LD211 
tended to reduce αSMA expression with higher concentrations but the changes did not 
reach statistical significance. However, Col3A1 expression decreased after treatment with 
a 10 nM (-8 M) concentration of LD211.  
 
 
Figure 14. Compilation of results from qPCR tests performed on primary neonatal cardiomyocytes after incubation 
with different concentrations of the melanocortin receptor 1 agonist for 3h. The genes assayed were αSMA (alpha 
smooth muscle actin), Col3A1 (collagen 3A1), IL-6 (interleukin 6) and Nppb (ventricular natriuretic peptide). One 
asterisk above a column denotes a P value lower than 0.05 when comparing that column to the control using a one-
way ANOVA and a later Tukey multiple comparison test. Data are presented as mean ± SEM, presented are 4 replicates 
per study condition and 6 for the controls. 
A concentration series was also performed to identify what concentration of PG 901 
causes the greatest effect in primary cardiomyocytes. In Figure 15, the effect of PG 901 
on αSMA expression is clear as all concentrations of the Mc5R agonist decrease its 
expression. Similarly, the expression of IL-6 is reduced after treatment with each 
concentration of PG 901 used. Both of these decreases are in line with those seen in the 
multiple agonist experiment. Furthermore, NOS2 expression was decreased after 10 pM 




Figure 15. Compilation of results from qPCR tests performed on primary neonatal cardiomyocytes after incubation 
with different concentrations of the melanocortin receptor 1 agonist for 3h. The genes assayed were αSMA (Alpha 
smooth muscle actin), NOS2 (Nitric Oxide Synthase 2), IL-6 (Interleukin 6) and Nppb (Ventricular natriuretic peptide). 
One asterisk above a column denotes a P value lower than 0.05 when comparing that column to the control using a 
one-way ANOVA and a later Tukey multiple comparison test. Two asterisks denote a P value lower than 0.01. Data 
are presented as mean ± SEM, presented are 4 replicates per study condition and 6 for the controls. 
 
2.2.4 Melanocortin receptor 5 knockdown in primary cardiomyocytes 
Based on the qPCR results, PG 901 was identified to be the most potent melanocortin 
receptor agonist to induce gene expression changes. These results indicated that Mc5R is 
the most interesting melanocortin receptor subtype to continue with future research. For 
this reason, we investigated whether silencing of Mc5R with small interfering RNA 
(siRNA) could produce opposite responses to what was seen after Mc5R activation with 
PG 901. The results of the first experiment are summarized in Figure 16. Knockdown of 
MC-5R for 24 h or 48 h   had no clear-cut effects on any of the genes studied. Subtle and 
non-significant increases were however observed in αSMA and NOS2 expression after 
24 h treatment with Mc5R-specific siRNA. It was of note that Mc5R was not either 
significantly reduced indicating insufficient knockdown of Mc5R. 
 
 
Figure 16. Compilation of results from qPCR tests performed on primary neonatal cardiomyocytes after Mc5R siRNA 
knockdown (K.D.) treatment for 24 and 48h. The sham knockdowns are designated by θ. The genes assayed were Nppa 
(atrial natriuretic peptide), NOS2 (nitric oxide synthase 2), Col1A2 (collagen 1A2) and Mc5R (melanocortin receptor 
5). Data are presented as mean ± SEM, presented are 6 replicates per study condition and 6 for the controls. 
Another experiment was performed with the Mc5R siRNA to test whether Mc5R cancels 
the effects of PG 901, the results of which can be seen in Figure 17. The Mc5R siRNA 
knockdown caused an increase in αSMA expression which was reverted by PG 901 
treatment. This further consolidated that the Mc5R-specific siRNA was ineffective in 
silencing Mc5R signalling as there was still a clear response to PG 901. However, Mc5R 
siRNA-treated cells showed an opposite phenotype to PG 901 treated cells, pointing 










































































































































































Figure 17. Compilation of results from qPCR tests performed on primary neonatal cardiomyocytes after Mc5R siRNA 
knockdown (K.D.) treatment for 24h and subsequent PG 901 -8M treatment for 3h. The sham knockdowns are 
designated by θ. The genes assayed were Nppb (ventricular natriuretic peptide), αSMA (alpha smooth muscle actin), 
Col3A1 (collagen 3A1) and TGF-β (transforming growth factor beta). One asterisk above a column denotes a P value 
lower than 0.05 when comparing that column to the control using a one-way ANOVA and a later Tukey multiple 
comparison test. Data are presented as mean ± SEM, presented are 6 replicates per study condition and 6 for the 
controls. 
3. Discussion  
Melanocortin signalling within cardiomyocytes has been proven to be more complex than 
previously known. In this study it was shown that different melanocortin receptor 
subtypes are present within cardiomyocytes and that their effects are sometimes 
antagonistic to each other, unveiling an underlying complexity previously unreported. To 
the knowledge of the author of this thesis  only Mc5R has been confirmed as playing a 
role in cardiac hypertrophy(Trotta et al., 2018). The results previously presented point to 
the high likelihood that other melanocortin receptors may play a significant role as well. 
It was found that α-MSH produced decreases in expression of cardiac remodelling and 
hypertrophic markers (αSMA, αSKA, TGF-β and Nppb) in H9c2 cells and in primary 










































































































































































































to be caused by Mc5R activation in H9c2 cells and by both Mc5R and Mc1R activation 
in primary mice cardiomyocytes. 
The attempts to study melanocortin signalling through using the phosphorylation of 
kinases was overall confusing. We observed some trends regarding a decrease in pJNK 
and pERK after PG 901 and LD211 treatment and after α-MSH, these however only 
appeared in some replicates, so the response was not consistent. Although not consistent 
overall the trends observed pointed to a decrease in pJNK and pERK which was 
promising as both are known to be involved in the signalling of NADPH oxidases after 
ischaemia, which leads to cardiac hypertrophy (Nabeebaccus et al., 2011). It is known 
that melanocortin receptors are G-protein-coupled receptors and have signalling 
dependant on cAMP, with CREB through PKA and ERK through the MAP/ERK 
pathway. JNK activation is driven through an increase in intracellular calcium. Despite 
these mediators being involved in the signalling of melanocortins, we were not able to 
optimize the ELISA tests to identify them consistently. Whether due to timing or 
sensitivity problems the exact cause of the experimental failure was not identified. All 
data from this first attempt at melanocortin receptor study had high variance and low 
replicability which could not be improved. After repeating those studies with a variety of 
parameters and only occasionally obtaining statistically significant results that 
disappeared upon replicating the study, it was decided to shelve these tests and approach 
the issue from a gene expression angle. The inconsistency in the significance of the results 
was attributed at this point to the very low amounts of protein detected and to the fact that 
α-MSH simultaneously activates multiple receptors that might lead to highly variable 
results.  
The qPCR tests had much lower data dispersion so their results will be valued over those 
of other methods. Initially, the results obtained from the qPCRs were still not clear. There 
were effects on some of the genes studied but those changes in expression vanished upon 
repeating the experiment or the direction of the effect even changed. The first qPCR tests 
were performed on samples treated with α-MSH and the pleiotropic effect of the pan-
agonist was thought to be a possible explanation for the inconsistent results. 
To test this hypothesis, a set of experiments was carried out using melanocortin receptor 
subtype-specific agonists. In the rat heart cell line H9c2, PG 901 (Mc5R agonist) reduced 
the expression of αSMA, αSKA TGF-β, IL-6, NOS2 and Col3A1. These decreases were 
reproduced when the experiments were repeated with primary mouse cardiomyocytes 
where PG 901 produced decreases in αSMA, IL-6, Nppb and NOS2. These results show 
 
that the activation of Mc5R has an overall protective effect on cardiac remodelling as it 
supresses the expression of remodelling markers (αSMA, αSKA, Nppb and Col3A1) and 
inflammatory markers (IL-6, TGF-β and NOS2). The effects of Mc5R activation are 
consistently protective against cardiac hypertrophy and show high reproducibility 
between models (αSMA, IL-6 and NOS2 expression was decreased in both models). 
In the same multiple melanocortin receptor agonist series of experiments, LD211 
increased IL-6 and NOS2 expression in H9c2 cells which was not replicated in primary 
cardiomyocytes. In contrast, LD211 reduced in αSMA, IL-6, Nppb and Col3A1 
expression in primary cardiomyocytes. The overlap in genes affected by both Mc5R and 
Mc1R activation in primary cardiomyocytes warrants further research to dissect the roles 
of these receptor subtypes in the regulation of cardiomyocyte growth and cardiac 
remodelling. It was also not possible to determine if there was some contamination of 
fibroblasts and or endothelial cells accounting for the LD211 response in the primary 
cardiomyocytes or whether it was caused by a true difference between the mouse 
cardiomyocytes and the rat cell line. Possible causative agents for this difference would 
be the difference between adult and neonatal cardiomyocytes, the species difference or a 
possible deviation of the cell line.  
The final set of experiments undertaken with the intent of studying gene expression was 
a Mc5R knockdown using siRNA in primary cardiomyocytes. The aim was to investigate 
whether silencing of Mc5R could lead to an opposite phenotype compared to cells that 
are activated by the Mc5R agonist PG 901. No clear-cut effects were seen in Mc5R 
siRNA-treated primary cardiomyocytes. The knockdown appears to not have been strong 
enough or long lasting-enough to significantly decrease the amount of Mc5R in the 
membrane of the cells and therefore affect their response to PG 901.  
In conclusion, the effects of melanocortin signalling in the heart are versatile and 
complex. A future line of investigation that remains open is to identify and characterize 
the exact role of melanocortin receptors, namely Mc1R and Mc5R, in cardiac remodelling 
process. The results here given provide a first proof of the presence and effect of 
melanocortin receptors in the heart and highlight the need for further research to unravel 
the role of melanocortins in the heart. 
Some experiments failed altogether, the results of which will be still provided in the 
Annex 3 as a guide for future research. Western blots attempting to analyse the protein 
levels directly instead of through mRNA expression failed to replicate the qPCR findings 
 
and showed no changes in protein expression with high inter-replicate variation. While 
possible it is highly improbable that all the gene expression changes observed with qPCRs 
were not translated to proteins at all. It is more likely that the methodology used for the 
western blots lacked the resolution to differentiate between the small changes in protein 
level brought on by the tested treatments. Furthermore, Col3A1 proved a very challenging 
protein to work with as we were not able to isolate a clear band of it even after attempting 
to use a native protein gel to allow the antibody to properly bind to the correct secondary 
structure of the protein. Every time anti-Col3A1 labelled antibodies were used 
background specks appeared, likely from environmental contamination of Col3A1. 
Future work with the same antibody should be performed in a clean hood to minimise this 
contamination. 
In this study, a general anti-fibrotic effect was observed for α-MSH in both cell types 
used and identified to be caused mostly by Mc5R activation. PG 901 caused decreases in 
hypertrophic genes and inflammation markers. Both αSKA and αSMA are upregulated 
during cardiac hypertrophy as they code for muscle proteins. Col3A1 as a building block 
of the extracellular matrix is known to be overexpressed during pathological cardiac 
remodelling. The decrease of expression of these genes forms the anti-hypertrophic 
effects of PG 901 found in both models. 
IL-6 is a pleiotropic cytokine, but it is mostly regarded as cardioprotective due to 
decreased inflammation. TGF-β is generally known to be pro-inflammatory so a decrease 
in its expression would be cardioprotective. NOS2 produces nitric oxide upon cell stress, 
the accumulation of which induces cardiomyocyte apoptosis which is then followed by 
inflammation and scarring.  The decrease of expression of these genes forms the anti-
inflammatory effects of PG 901 found in both models. Finally, Nppb is hypertrophy 
marker so a decrease in this gene is in line with a cardioprotective effect of PG 901.  
In conclusion, the results of this study point to a protective effect from cardiac 
hypertrophy of activation of Mc5R and to a lesser degree also Mc1R. Another study 
(Trotta et al., 2018) has found a potential cardioprotective effect of Mc5R activation in 
high-glucose induced hypertrophy which could be just one aspect of a general 
cardioprotective role of these receptors. If this were to be the case, there is the possibility 
that further research into this protective effect would end up with the development of a 
Mc5R agonistic treatment post-ischaemia to protect from cardiac remodelling and 
increase the long-term survival of those patients. 
 
3.1 Methodological considerations 
To study the potential effects of melanocortin modulation on cardiac hypertrophy it is 
paramount to use adequate models. To reduce the usage of test animals, the first 
experiments were performed in H9c2 cells. It is an established commercial rat 
cardiomyocyte cell line that has widely been used to model cardiac response and is 
especially reliable in regards to hypertrophy study and drug metabolism (Hescheler et al., 
1991; Zordoky and El-Kadi, 2007; Watkins et al., 2011). 
Established cell lines have many ethical, technical and financial advantages which entitles 
their use as experimental models over in vivo models. However, there might be some 
notable differences e.g. in gene expressions and metabolism which need to be considered. 
Therefore, it is valuable to verify results with primary cells and/or in vivo experiments.  
Primary neonatal cardiomyocytes are used in cardiac research over adult ones, since they 
are easier to culture in vitro while they still reproduce cardiac metabolism and cell 
morphology (Sreejit et al., 2008; Watkins et al., 2011). Both, rat and mouse neonatal 
cardiomyocytes are routinely used, but mice are easier to breed and overall cheaper to 
acquire. 
4. Materials and methods  
4.1 H9c2 cell line 
A rat cardiomyocyte cell line sourced from ATCC with the identifier: H9c2(2-
1) (ATCC® CRL1446™). This cell line was created by cloning an embryonic BDIX rat 
cardiac tissue and has been used since as a model for cardiac drug development (Kimes 
and Brandt, 1976). It has been characterized as a good model for cardiac metabolism and 
preserves many of the surface markers of an in vivo cardiomyocyte but lacks some of the 
morphological properties of primary cardiomyocyte culture; e.g. gap junctions, T tubules 
or organized sarcomeres along myofibrils (Hescheler et al., 1991). These cells were used 
at passage numbers ranging from 12 to 20. Stocks were kept in liquid nitrogen and thawed 
when needed. H9c2 cells were cultured in high glucose DMEM (4500mg/l, Sigma-
Aldrich) supplemented with 1% Penicillin + Streptomycin and 10% foetal bovine serum 
(FBS). In maintenance cultures the medium was changed every third day and subcultured 
with dividing ratios ranging from 1:3 to 1:5 every third day or when confluency exceeded 
80%. For experiments, cells were plated at 90.000 cells per 6-well plate or 50.000 cells 
per 12-well plate and let to grow until confluency in the wells reached between 60-70%. 
 
4.2 Primary cardiomyocytes 
Primary cardiomyocyte isolation was performed according to a revised version of Thermo 
Fisher’s Pierce Primary cardiomyocyte isolation kit (Thermo Scientific). 0-3-day old 
C57Bl/6NCrl mice were euthanized, and their hearts were extracted and moved into a 
petri dish with ice-cold HBSS. On the dish, the hearts were cleaned with the use of 
tweezers and a scalpel to obtain pure myocardium. The isolated hearts were then 
transferred into 2 mL centrifuge tubes ranging from 500 µL to 1 mL of HBSS depending 
on the number of hearts (2-4). The hearts were then minced on-site at the animal facility 
using scissors until pieces are all smaller than 3mm in any direction. The hearts were then 
moved to a primary cell lab where they were digested using the kit’s enzyme mixture and 
the final cell suspension was quantified using an automated cell counter gated between 4 
and 12 µm (Judd et al., 2016) to count all cardiomyocytes and exclude other cell types. 
The cells were then plated to the final 500.000 cell/well concentration in 24-well plates 
in DMEM supplemented with 1% Penicillin + Streptomycin and 10% FBS. After 24h, 
the medium was refreshed and supplemented with cardiomyocyte growth supplement. 
The medium was refreshed again after 72 h and experiments were carried out 6-7 days 
post-extraction. 
4.3 Elisa assays for quantifying intracellular signalling responses 
ELISA assays were performed to detect the presence of phosphorylated CREB, JNK and 
ERK-1 using ELISA kits (DuoSet ELISA, R&D Systems). Results were normalised for 
total amount of protein using Thermo Fisher’s Pierce BCA Protein Assay Kit (PierceTM 
BCA Protein Assay Kit). These tests were performed as stated in their respective 
instructions while never breaking a chain of cold for the samples until they were pipetted 
ice-cold into the ELISA plate. 
4.4 qPCR 
RNA extraction was performed using either QIAzol (QIAGEN) and then purified with 
Zymo-Research’s Quick-RNA kits (Quick-RNA Microprep for primary cardiomyocytes 
and Quick-RNA Miniprep for H9c2 cells). Samples were reverse-transcribed 
(PrimeScript RT reagent kit, Clontech) and then diluted with nuclease free water before 
performing a RT-PCR using a 2720 Applied Biosystems Thermal Cycler and predesigned 
primer and probe mix SYBR Green protocols (Kapa Biosystems) using the primer 
sequences given in Annex 2. Target protein expression was normalized to GADPH (H9c2 
 
cells) or β-actin (primary cardiomyocytes), and the fold induction was calculated using 
the comparative ΔCt method and are presented as relative transcript levels (2-ΔΔCt). 
4.5 Melanocortin receptor agonists 
To study the individual effects of activation of different melanocortin receptor subtypes 
and identify which melanocortin receptors are responsible for hypertrophy protecting 
effects the melanocortin receptor agonists LD211, γ-MSH, PG 901 and THIQ were used. 
LD211 is a Mc1R-specific agonist that has been previously described in published 
literature  (Doedens et al., 2010). In Doedens et. al. LD211 was described as compound 
28. γ-MSH is a Mc3R-specific agonist, in this study D-Trp8-γ-MSH was used (Grieco et 
al., 2000). THIQ is a synthetic Mc4R-specific agonist (Pogozheva et al., 2005). PG 901 
is a Mc5R-specific agonist with an antagonist role against Mc4R (Grieco et al., 2002).  
α-MSH was used as a pan-agonist that activates melanocortin receptors 1, 3, 4 and 5 in 
decreasing order of affinity (Schiöth et al., 1997). 
4.6 Mc5R siRNA knockdowns 
To corroborate that the effects of PG 901 were caused through Mc5R activation a 
knockdown of the receptor gene was carried out by means of siRNA reduction of gene 
expression. A temporary interference in the production of Mc5R was expected to decrease 
the levels of the receptor present in the membranes to a level that a noticeable change in 
PG 901 response could be observed. The knockout was performed in accordance with 
Thermo Scientific’s “Lipofectamine® RNAIMAX transfection protocol” using 6-well 
plates and using the negative control siRNA (a non-targeting siRNA) with the catalog 
number 4390843 and the Mc5R siRNA with catalog number 4390771 (which corresponds 
to the mouse Chr.18: 68337260 - 68342446 on Build GRCm38). Both siRNAs were also 
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6. Abbreviations list  
ACTH: adrenocorticotropic hormone 
ANP: atrial natriuretic peptide 
BNP: brain natriuretic peptide 
CCL2: C-C motif chemokine Ligand 2 
Col3A1: collagen 3 A 1 
CREB: cAMP response element-binding protein 
ERK: extracellular signal-regulated kinases 
HFpEF: heart failure with preserved ejection fraction 
HFrEF: heart failure with reduced ejection fraction 
IL-6: interleukin 6 
Mc1R: melanocortin 1 receptor 
Mc2R: melanocortin 2 receptor 
Mc3R: melanocortin 3 receptor 
Mc4R: melanocortin 4 receptor 
Mc5R: melanocortin 5 receptor 
NOS2: nitric oxide synthase 2 
pCREB: phosphorylated CREB 
pERK: phosphorylated ERK 
 
pJNK: phosphorylated JNK 
POMC: pro-opiomelanocortin 
α-MSH: alpha melanocyte stimulating hormone 
αSKA: alpha skeletal actin 
αSMA: alpha smooth muscle actin 
γ-MSH: gamma melanocyte stimulating hormone 
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A. Appendices  
A1: Raw experimental data 
Raw data can be downloaded from: 
https://drive.google.com/file/d/1REUMAxsnjHnRb8xxjyHykG4yXr_gqE76/view?usp=
sharing 
A2: Supplementary graphs 
Supplementary graphs can be downloaded from: 
https://drive.google.com/file/d/1J1c_5iBFTn12D9nR7FQ8tPchQrL-
TEtf/view?usp=sharing 
A3: Methods excluded from main body of thesis 
A3.1 Western Blot 
Western blots were carried out according to an in-house protocol previously described in 
published article (Rinne et al., 2017). Cells were lysed using RIPA buffer, proteins were 
separated by size through SDS-polyacrylamide gel electrophoresis and then transferred 
to nitrocellulose membranes. After a blocking step with BSA, membranes were probed 
with primary antibodies followed by detection with HRP-linked secondary antibodies, all 
antibodies used can be found in Table 1. Target protein expression was normalized to 
correct for loading imbalances to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
or β-actin depending on target protein size and potential overlap with target protein bands.  
Table 1. Compilation of all antibodies used for western blotting. Target protein information can be found in the target 
and target organism columns. The source refers to the IgG heavy chain origin. Working dilution and providing 
company are also included. 
Target Target 
organism 
Source Dilution Company 
Col3A1   Mouse Rabbit 1:2000 Novusbio 
TGF-β1 Mouse Rabbit 1:2000 Novusbio 
αSMA Mouse Rabbit 1:2000 Sigma-Aldrich 













Membranes were imaged using Sapphire Biomolecular Imager from Azure Biosystems 
and stripped for reprobing using Abcam’s stripping protocol using the mild stripping 
buffer therein described. 
A3.1.1 Native gel electrophoresis 
For the purpose of analysing Col3A1, a native gel electrophoresis was performed 
according to a protocol by the Institute of Molecular Development published in 2012. The 
protocol was followed without significant changes. The separating gel was 5 % 
acrylamide, and the de-gassing was performed with an air pump set at -5 atmospheres. 
A3.2 Leucine incorporation assay 
To assay overall changes in protein production, tritium-labelled [3H] leucine 
incorporation assays were performed. When the cells had reached a confluence level of 
80-90% per well, the medium was changed and replaced with new medium containing 
tritium-labelled leucine (1-2 μCi/ml medium, Perkin Elmer). After medium change, cell 
were treated with melanocortin receptor agonists and allowed to grow for 24-48h. After 
medium aspiration and two PBS washes, proteins were precipitated using 10% 
tricloroacetic acid (TCA) and incubated at 4°C for 30 min. Cells were then washed twice 
using ice-cold MilliQ water and lysed with 0.5 M NaOH (200 µL/well). After adding 
NaOH into wells, plates were kept 10-20 minutes at 37°C and thereafter wells were 
scraped with plastic cell scrapers to ensure complete removal of cells from the wells. Cell 
lysates were then collected into Eppendorf tubes. 100 µL of each sample were added to 3 
ml of LSC cocktail (Optiphase Supermix, Perkin Elmer) into liquid scintillation vials. 
Samples were then measured with Hidex 600 SL Automatic liquid scintillation counter at 
5 min count time per vial. 
 
 
 
